Natasha Muench wrote a new post 3 weeks, 3 days ago
Reflecting on ENTERO 2024 – A Milestone for Early-Age Onset Digestive Cancers
On November 14 and 15, Digestive Cancers Europe (DiCE) and EuropaColon Portugal proudly hosted ENTERO 2024 in the scenic city of Porto, […]-
Natasha Muench wrote a new post 3 weeks, 5 days ago
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
On October 17, 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) endorsed two new therapeutic indications f […] -
Natasha Muench wrote a new post 1 month, 3 weeks ago
New Era in Gastric Cancer Treatment: Zolbetuximab Gains EU Approval
On 20 September 2024, the European Commission approved zolbetuximab in combination with chemotherapy to treat advanced and metastatic Gastric and […] -
Natasha Muench changed their profile picture 10 months ago
-
Natasha Muench wrote a new post 10 months ago
Positive Response to New Neoadjuvant Treatment Combination for Gastric and Gastroesophageal Cancer
Despite advances in treatment options, most patients diagnosed with non-metastatic((cancer that has not yet spread to other organs) gastric or […] -
Natasha Muench wrote a new post 1 year ago
Celebrating a Lifetime of Achievement: Dr Eric Van Cutsem Honoured as Professor Emeritus
Dr Eric Van Cutsem, world-renowned Professor of Clinical Digestive Oncology and co-founder of Digestive Cancers Europe, was lauded as Professor […] -
Natasha Muench wrote a new post 1 year, 2 months ago
Economist Impact: World Cancer Series Europe
On 20 September, the Belgian delegation of the DiCE Team attended the Economist Impact’s World Cancer Series: Europe in Brussels, proudly supporting […] -
Natasha Muench wrote a new post 1 year, 2 months ago
Do You Dare to Think Differently about Cancer?
The Cancer Grand Challenges mission is “Uniting the World’s brightest minds against cancer’s toughest […] -
Natasha Muench wrote a new post 1 year, 5 months ago
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicine […] -
Natasha Muench wrote a new post 1 year, 5 months ago
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including […] -
Natasha Muench wrote a new post 1 year, 10 months ago
The devastating earthquakes that struck southern Turkey and northern Syria on 6 February have destroyed homes, […] -
Natasha Muench wrote a new post 1 year, 10 months ago
<strong>DiCE Supports Act4Biosimilars to Increase Patient Access to Biologic Medicines</strong>
Act4Biosimilars is a global initiative that aims to increase patient access to biologics by facilitating greater […] -
Natasha Muench wrote a new post 1 year, 10 months ago
<strong>16 February is World Cholangiocarcinoma Day</strong>
16 February is World Cholangiocarcinoma (CCA) Day. World CCA Day was previously held on 12 February. However, […] -
Natasha Muench wrote a new post 2 years, 9 months ago
The two most common types of oesophageal cancer are squamous cell carcinoma (OSCC) and adenocarcinoma (OAC). The majority of oesophageal cancers belong to the OSCC sub-type, accounting for more than 85% of all […]
-
